Novo Nordisk's insulin aspart franchise is a ... having a biosimilar option for their rapid-acting insulin injection can truly make a difference, as biosimilar products have the potential to ...

Novo Nordisk is also pairing the long-acting insulin with its once-weekly GLP-1 agonist semaglutide in the COMBINE trials programme, which is due to complete in 2024, is also working on a glucose ...

Victoza, produced by Novo Nordisk, holds FDA approval for regulating blood sugar levels among individuals diagnosed with type ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

https://www.tipranks.com/news/the-fly/novo-nordisk-warns-of-counterfeit-ozempic-injections Novo Nordisk (NVO) said it has become aware of several hundred units of ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral weight-loss drug news and BMO cut its rating for the Danish drug developer's ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NVO)'s share was trading at $64.49 ...

Representative C. Scott Franklin (R-Florida) recently bought shares of Novo Nordisk A/S (NYSE:NVO). In a filing disclosed on April 11th, the Representative disclosed that they had bought between $ ...

BNP Paribas Exane initiated coverage of Novo Nordisk with a recommendation of underperform and a Street-low price target of DKK405.00. The broker cites the obesity drugmaker’s valuation ...